Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 119,300 shares, a growth of 9.4% from the November 30th total of 109,000 shares. Based on an average trading volume of 4,500 shares, the short-interest ratio is currently 26.5 days.
Genmab A/S Trading Down 0.8 %
GNMSF stock traded down $1.74 during midday trading on Tuesday, hitting $207.38. 801 shares of the company's stock were exchanged, compared to its average volume of 2,809. Genmab A/S has a 1-year low of $192.20 and a 1-year high of $334.33. The stock has a market capitalization of $13.56 billion, a PE ratio of 19.94 and a beta of 1.03. The business has a 50-day simple moving average of $214.62 and a two-hundred day simple moving average of $242.16.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
